NewAmsterdam Pharma N.V. (NAMS) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 29.2% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -66.3% for RCUS. Arcus Biosciences is the larger company by market cap ($2.25 billion vs $2.21 billion), about 1.0 times the size.
Arcus Biosciences converts more of its revenue into profit, with a net margin of -142.9% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | RCUS |
|---|---|---|
| Share price | $18.41 | $15.62 |
| Market cap | $2.21B | $2.25B |
| 1-day change | -5.64% | -1.01% |
| YTD return | -47.52% | -34.45% |
| 1-year return | -51.89% | -29.16% |
| 5-year return | +88.05% | -66.31% |
| EPS (TTM) | $-1.69 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $247.00M |
| Revenue growth (YoY) | -50.61% | -4.26% |
| Net income (latest FY) | $-203.82M | $-353.00M |
| Operating margin | -1002.90% | -156.28% |
| Net margin | -905.74% | -142.91% |
| 52-week high | $42.21 | $31.74 |
| 52-week low | $17.90 | $15.56 |
| Distance from 52-week high | -56.38% | -50.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +174.85% | +162.48% |
| Average volume | 1.66M | 1.85M |
| Shares outstanding | 119.93M | 143.99M |
| Employees | 100 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed NAMS by 22.7 percentage points over the past year.
- Arcus Biosciences is more profitable, keeping -142.9 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Arcus Biosciences grew revenue faster in its latest fiscal year (-4.26% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
NAMS vs RCUS FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $2.25B compared with $2.21B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, NAMS or RCUS?
RCUS returned -29.16% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.